Penn to reduce graduate admissions, rescind acceptances amid research cuts

Endowments and Why They “Can’t Just Pay”

• Many commenters start from “Penn has a $22B endowment, why not use it?”
• Others explain endowments as restricted, long‑horizon trust funds: principal is legally locked, returns are mostly pre‑earmarked (chairs, scholarships, specific fields), and schools typically spend ~4–5% annually.
• Several note that even endowment income is often too constrained or small (1–2% practically spendable for research), so it can’t simply backfill large, sudden federal cuts.

Grad Students, Stipends, and the PhD Pipeline

• Strong criticism that universities work grad students “to the bone” for poverty stipends while taking large overheads.
• Some argue low stipends can still be attractive for certain students, but others emphasize mental‑health crises, slum‑like living conditions, and exploitative dynamics.
• Debate over whether the US produces “too many PhDs” (especially in some fields) versus the need to maintain a robust, relatively cheap scientific workforce and pharma pipeline.

Indirect Costs (Overhead) and the 15% Cap

• Confusion and argument over what a 59% indirect rate means; multiple comments clarify it is 59% on direct costs (so ~37% of total), and many expenses (equipment, tuition) are exempt.
• Supporters of the cap see 50–90% rates as proof of waste and cross‑subsidy; critics say indirects pay for labs, utilities, compliance, IT, safety, core facilities, and shared staff that enable research.
• Several point out that current rates are painstakingly negotiated with NIH/NSF and governed by regulation; abrupt across‑the‑board cuts are described as likely illegal and highly disruptive.

Administrative Bloat vs. Necessary Staff

• Widely shared data on explosive growth of non‑faculty employees fuels anger that universities cut PhD spots instead of administrators.
• Counterarguments: much “admin” is actually scientific staff, compliance, IRB, immigration, tech transfer, research computing, etc., driven by regulatory and service expansion.
• Some note genuine bloat (multiple IT silos, amenities arms race), but argue blunt overhead cuts will mostly hurt essential support and push more burdens onto faculty and grad students.

Political Motives and Legality

• Many see the NIH indirect cuts and grant slowdowns as a deliberate, shock‑and‑awe move by the current administration to weaken universities and the scientific establishment, not a good‑faith efficiency reform.
• Others welcome a chainsaw approach, arguing that gradual, consultative reform has failed and entrenched institutions will otherwise block change.
• Legal discussion centers on appropriations law, NIH regulations, and court orders temporarily restraining aspects of the policy.

Consequences for Research, Industry, and Equity

• Reports of multiple programs (biochemistry, biostatistics, “bio‑” departments) admitting zero PhD students; individual PIs are freezing hiring to protect current trainees.
• Concerns that US biomedical and biotech leadership will erode, with talent and research shifting to Europe/Asia and private foundations or foreign governments.
• Worries that access to advanced education will skew further toward the rich as funded PhD paths shrink, and that research slowdowns (e.g., in mRNA, Alzheimer’s) carry large long‑term social and economic costs.